Roche inaugurates new R&D building in Basel
Basel, 25 November 2011
Investment of roughly CHF 250 million in centre for technical research and development
Today Roche announced the opening of a new R&D building in Basel. The facility, which represents an investment of CHF 250 million, will be used to investigate and develop pharmaceutical formulations for new active ingredients, as well as manufacture supplies for global clinical trials.
"Finding the safest and most efficient formulation for an active ingredient is a key part of the drug development process." said Roche Group CEO Severin Schwan. “Functions from the entire pharmaceutical value-chain are located in Basel. This investment further strengthens the role of Basel headquarters and as a global centre for research and development. “
"Basel is a global centre of excellence for innovative formulation processes. By expanding our capacity in this field, we will be able to respond even more effectively to patients' needs and make medication easier to use“, added Matthias M. Baltisberger, Head of the Basel Site. „This will be the first time in Roche's history that employees in technical research and development will actually be sharing the same working area. By working together in close proximity they will be able to collaborate even closer on this pivotal aspect of drug development."
About technical research and development at Roche
Technical research and development are important stages in the development of a medicine. Activities focus on methods of processing new active ingredients into tablets, capsules and injectable dosage forms in vials and prefilled syringes. It is this formulation that makes it possible to administer a drug to humans: it optimises the amount of active ingredient that reaches its target and the length of time the drug remains in the patient's body (bioavailability). Many new active substances require specific and innovative technologies to make them available in the body after they have been swallowed.
About the R&D building (Building 97)
The new R&D building is the first step in renewing the site along Wettsteinallee. Its architecture is intended to guide future development.
The building designed by Herzog & de Meuron echoes the architectural style defined by Otto Salvisberg for Roche and continues long-standing development practices at the site.
High-quality architecture in the Bauhaus tradition has been the hallmark of Roche's buildings since the early 20th century.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.